Sweden-based biotics solutions company Probi, a subsidiary of German chemicals company Symrise AG (ETR: SY1), announced on Wednesday that it has expanded its portfolio with two new categories: Sports & Active Nutrition by Probi and Pets by Probi.
The company said the launches advance its strategy to deliver clinically documented biotic solutions that support health for both humans and animals.
Probi noted rising demand for natural, science-based products in active nutrition, citing a 15.4% increase in US performance nutrition sales in 2024 and stronger global supplement usage.
Sports & Active Nutrition by Probi is built around the probiotic strain L. plantarum 299V, developed to support cardio-respiratory function, digestive comfort during exercise, circulatory health, endurance and vitality.
Probi is also entering the pet supplement market with two probiotic solutions for dogs and cats, targeting digestive health and oral health. The Pets by Probi range features the strain L. plantarum 6595 for digestive support and S. salivarius BLIS K12 and BLIS M18 for oral care, supported by a revised agreement granting Probi exclusive distribution rights for the BLIS strains in selected markets.
The company added that it has secured National Animal Supplement Council Preferred Supplier certification in the United States, reflecting its focus on quality and safety in companion animal health.
Probi launches new human and pet biotics ranges
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
Avacta reports promising Phase 1a data for faridoxorubicin at ESMO 2025
Jacobio Pharma partners with Oceanpine Capital to focus on core oncology pipeline
Johnson & Johnson to separate its Orthopaedics business as standalone DePuy Synthes
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Amgen offers Repatha through AmgenNow direct-to-patient programme
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST